Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Xinwei Hua, Ninghao Huang, Tao Huang, Rui Li, Zimin Song, Yi-Da Tang, Wenxiu Wang

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: United States : JAMA cardiology , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 723945

 IMPORTANCE: Despite substantial progress in low-density lipoprotein cholesterol (LDL-C)-lowering strategies, residual cardiovascular risk remains. Apolipoprotein C3 (APOC3) has emerged as a novel target for lowering triglycerides. Multiple clinical trials of small-interfering RNA therapeutics targeting APOC3 are currently underway. OBJECTIVE: To investigate whether genetically predicted lower APOC3 is associated with a reduction in cardiovascular risk and if the combined exposure to APOC3 and LDL-C-lowering variants is associated with a reduction in the risk of coronary heart disease (CHD). DESIGN, SETTING, AND PARTICIPANTS: This was a population-based genetic association study with 2 × 2 factorial mendelian randomization. Included were participants of European ancestry in the UK Biobank. Data were analyzed from November 2023 to July 2024. EXPOSURES: Genetic scores were constructed to mimic the effects of APOC3, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors. MAIN OUTCOMES AND MEASURES: Plasma lipid and lipoprotein levels, CHD, and type 2 diabetes (T2D). RESULTS: This study included 401 548 UK Biobank participants (mean [SD] age, 56.9 [8.0] years
  216 901 female [54.0%]). Genetically predicted lower APOC3 was associated with a lower risk of CHD (odds ratio [OR], 0.96
  95% CI, 0.93-0.98) and T2D (0.97
  95% CI, 0.95-0.99). Genetically lower APOC3 and PCSK9 were associated with a similar magnitude of risk reduction in CHD per 10-mg/dL decrease in apolipoprotein B (ApoB) level (APOC3: 0.70
  95% CI, 0.59-0.83
  PCSK9: 0.71
  95% CI, 0.65-0.77). Combined exposure to genetically lower APOC3 and PCSK9 was associated with an additive lower risk of CHD (APOC3: 0.96
  95% CI, 0.92-0.99
  PCSK9: 0.93
  95% CI, 0.90-0.97
  combined: 0.90
  95% CI, 0.86-0.93). Genetically lower HMGCR was also associated with a lower risk of CHD, and the risk was further reduced when combined with APOC3 (0.93
  95% CI, 0.90-0.97). CONCLUSIONS AND RELEVANCE: Genetically predicted lower APOC3 was associated with a reduced risk of CHD that is comparable with that associated with lower PCSK9 per unit decrease in ApoB. Combined exposure to APOC3 and LDL-C-lowering variants was associated with an additive reduction in CHD risk. Future studies are warranted to investigate the therapeutic potential of these combined therapies, particularly among high-risk patients who cannot achieve therapeutic targets with existing lipid-lowering therapies.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH